Style | Citing Format |
---|---|
MLA | Rezazadeh M, et al.. "Preparation and Characterization of Eudragit L 100-55/Chitosan Enteric Nanoparticles Containing Omeprazole Using General Factorial Design: In Vitro/In Vivo Study." Research in Pharmaceutical Sciences, vol. 16, no. 4, 2021, pp. 358-369. |
APA | Rezazadeh M, Safaran R, Minaiyan M, Mostafavi A (2021). Preparation and Characterization of Eudragit L 100-55/Chitosan Enteric Nanoparticles Containing Omeprazole Using General Factorial Design: In Vitro/In Vivo Study. Research in Pharmaceutical Sciences, 16(4), 358-369. |
Chicago | Rezazadeh M, Safaran R, Minaiyan M, Mostafavi A. "Preparation and Characterization of Eudragit L 100-55/Chitosan Enteric Nanoparticles Containing Omeprazole Using General Factorial Design: In Vitro/In Vivo Study." Research in Pharmaceutical Sciences 16, no. 4 (2021): 358-369. |
Harvard | Rezazadeh M et al. (2021) 'Preparation and Characterization of Eudragit L 100-55/Chitosan Enteric Nanoparticles Containing Omeprazole Using General Factorial Design: In Vitro/In Vivo Study', Research in Pharmaceutical Sciences, 16(4), pp. 358-369. |
Vancouver | Rezazadeh M, Safaran R, Minaiyan M, Mostafavi A. Preparation and Characterization of Eudragit L 100-55/Chitosan Enteric Nanoparticles Containing Omeprazole Using General Factorial Design: In Vitro/In Vivo Study. Research in Pharmaceutical Sciences. 2021;16(4):358-369. |
BibTex | @article{ author = {Rezazadeh M and Safaran R and Minaiyan M and Mostafavi A}, title = {Preparation and Characterization of Eudragit L 100-55/Chitosan Enteric Nanoparticles Containing Omeprazole Using General Factorial Design: In Vitro/In Vivo Study}, journal = {Research in Pharmaceutical Sciences}, volume = {16}, number = {4}, pages = {358-369}, year = {2021} } |
RIS | TY - JOUR AU - Rezazadeh M AU - Safaran R AU - Minaiyan M AU - Mostafavi A TI - Preparation and Characterization of Eudragit L 100-55/Chitosan Enteric Nanoparticles Containing Omeprazole Using General Factorial Design: In Vitro/In Vivo Study JO - Research in Pharmaceutical Sciences VL - 16 IS - 4 SP - 358 EP - 369 PY - 2021 ER - |